Amneal Pharmaceuticals, Inc.
AMRX
$10.48
$0.121.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 724.51M | 695.42M | 730.52M | 702.47M | 701.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 724.51M | 695.42M | 730.52M | 702.47M | 701.78M |
| Cost of Revenue | 440.27M | 441.30M | 468.58M | 434.88M | 452.88M |
| Gross Profit | 284.24M | 254.12M | 261.94M | 267.59M | 248.91M |
| SG&A Expenses | 124.27M | 118.29M | 128.69M | 118.69M | 116.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -5.12M | -- | -- | -- |
| Total Operating Expenses | 612.50M | 594.50M | 651.53M | 614.67M | 605.39M |
| Operating Income | 112.01M | 100.92M | 78.99M | 87.80M | 96.39M |
| Income Before Tax | 51.71M | 37.49M | -15.32M | 15.42M | 20.41M |
| Income Tax Expenses | 16.10M | 12.87M | 5.42M | 3.67M | 3.62M |
| Earnings from Continuing Operations | 35.61M | 24.62M | -20.74M | 11.76M | 16.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.19M | -12.42M | -10.34M | -11.91M | -10.79M |
| Net Income | 22.42M | 12.20M | -31.08M | -156.00K | 5.99M |
| EBIT | 112.01M | 100.92M | 78.99M | 87.80M | 96.39M |
| EBITDA | 172.12M | 161.08M | 145.12M | 146.76M | 151.96M |
| EPS Basic | 0.07 | 0.04 | -0.10 | 0.00 | 0.02 |
| Normalized Basic EPS | 0.06 | 0.04 | -0.07 | -0.01 | 0.00 |
| EPS Diluted | 0.07 | 0.04 | -0.10 | 0.00 | 0.02 |
| Normalized Diluted EPS | 0.06 | 0.04 | -0.07 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 313.74M | 311.05M | 309.85M | 309.65M | 309.12M |
| Average Diluted Shares Outstanding | 322.36M | 323.96M | 309.85M | 309.65M | 318.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |